Blog

Clinical research site organisations are entering a new era of growth. Expansion is no longer defined solely by mergers and acquisitions but also by workforce development, increased operational capability, diversification into new therapeutic areas, higher study volumes, and broader geographic reach. While these developments create significant opportunities, they also introduce increasing operational complexity.

We are delighted to share some exciting news with you about the next chapter in the growth of IAOCR.

Clinical research is the cornerstone of medical innovation, driving the development of new treatments, therapies, and interventions that improve patient outcomes worldwide. However, the complexity of international clinical trial delivery spanning multiple countries, compounded by international and local regulatory requirements and local healthcare system variations, demands the most rigorous quality standards across all research sites involved, for overall trial success.

At a recent industry conference, the Quality Director of a rapidly expanding research site network approached our GCSA Site Certification stand to discuss a growing concern. Following an injection of external investment, their organization had scaled quickly through acquisition bringing multiple new independent sites into the network.

Competence-based clinical research training has become a buzzword across education, corporate learning, and professional certification. The promise is compelling: instead of focusing on time spent in a classroom, learners advance by demonstrating real skills and measurable ability. In theory, competence, not attendance, becomes the currency. But this raises a critical question: if training is truly competence-based, where is the evidence of competence?

In the clinical trials industry, Key Performance Indicators (KPIs) have long been dominated by the ‘First Participant, First Visit’ (FPFV) metric. Sponsors, CROs, and sites alike celebrate the speed at which a trial enrolls its first participant as a major milestone. While there’s no denying that FPFV represents momentum and is often a key financial milestone, there’s growing concern that overemphasis on this single point in time creates a narrow view of trial success, potentially overshadowing more meaningful outcomes further down the line.

In today’s competitive clinical research environment, organisations are under increasing pressure to attract, develop, and retain high-performing clinical research professionals, while maintaining the highest standards of quality, compliance, and participant safety.

More clinical research sites are exploring certification to formally embed and demonstrate quality, strengthen sponsor confidence, and differentiate themselves in an increasingly competitive landscape.

Saudi Arabia is increasingly part of global conversations in clinical research, yet for many western professionals, the prospect of travelling to the Kingdom raises questions about unknowns. Therefore, I wanted to share my first-hand perspective and experience to support others in clinical research (and generally) who may be considering business travel to Saudi Arabia.